Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) has submitted a supplemental new drug application (SNDA) to the U.S. Food and ...

The drug has shown strong results in phase 3 clinical trials, which are the basis for the new application to the FDA.

A study reveals that combining fitness tracker data with machine learning algorithms can effectively predict mood episodes in ...

Intra-Cellular submitted its application to the FDA for Caplyta’s approval in major depressive disorder, potentially opening ...

What is muscle dysmorphia? This mental health condition primarily affects men and social media platforms could be to blame.

The Bipolar Disorder Drugs and Treatment Market is projected to grow at a CAGR of 2.72%, reaching USD 5.8 billion by 2033.

Researchers have worked with health partners in east Africa to unveil an integrated care model for treating major depressive disorder.

Therapies announced that it has recently submitted a supplemental New Drug Application, sNDA, to the U.S. Food and Drug ...

Javier Muniz, M.D. - Vice President of Research and Development Strategy, MindMed (Photo: Business Wire) ...

Common signs of depression include: n Feeling sad or down most of the day, nearly every day (in children, this might appear as anger or irritability) For about 5% of people in the U.S., especially in ...

About one-third of U.S. adults without diabetes who are eligible for weight loss treatment with glucagon-like peptide 1 ...

Research has shown that obstructive sleep apnea is an independent risk factor for depression, anxiety, and, more importantly, ...